The Asia Pacific vaccines market is expected to reach US$ 12,631.4 Mn in 2027 from US$ 7,254.5 Mn in 2018. The market is estimated to grow with a CAGR of 6.4% from 2019-2027.
Every year thousands of children in Asia Pacific region die, and many more are hospitalized due to diseases which are preventable by vaccines. The treatment cost of these diseases is very high. According to the Gavi, the Vaccine Alliance, one in every five children in Asia Pacific region don't have access to basic vaccines. Thus in Asia Pacific region, many awareness programs have been undertaken by the government in order to raise awareness among the population. The Immunization Partners in Asia Pacific (IPAP) arranged the 6th Asian Vaccine Conference (ASVAC 2017), in April 2017at Singapore. The countries in the Asia Pacific region are joining forces to eradicate infectious diseases like measles, diphtheria, rubella, pertussis, and others through vaccinations. There are several vaccination programs, campaigns, conferences, being held in the Asia Pacific region in order to raise awareness among the population. For instance, India, along with other WHO South East Asia Region member countries, has initiated a campaign to eradicate measles and control rubella/congenital rubella syndrome (CRS) by 2020. The campaigns by the Ministry of Health & Family Welfare aims to immunize 41 crore children in India. The first phase of the campaign was successfully completed in February 2017 in five states, namely, Tamil Nadu, Karnataka, Goa, Lakshadweep, and Puducherry. Over 3.3 crore children were vaccinated, reaching out to 97% of the targeted age group. The campaign was conducted in schools, community centers, and other health facilities.
In 2018, the conjugate vaccines segment held the largest market share of 27.2% of the vaccines market, by type. This segment is also expected to dominate the market in 2027 owing to the advantages offered by the vaccines for diseases such as pneumonia and others. Furthermore, the conjugate vaccines segment is anticipated to witness the significant growth rate during the forecast period, 2019 to 2027.
Asia Pacific vaccines market by the disease indication was led by the other segments, which has included diseases such as poliomyelitis (polio), measles, mumps, rubella, pneumococcal infections, and others. The others segment has the largest market share in 2018, which accounted for 59.6% and is expected to dominate the market in 2027. Similarly, the vaccines market by the route of administration was led by the injectable segment. Whereas, the market of the vaccines in the Asia Pacific by the patient type was led by the pediatric segment.
Some of the major primary and secondary sources for vaccines included in the report are Immunization Partners in Asia Pacific (IPAP), Food and Drug Administration, World Health Organization, National Polio Surveillance Project (NPSP), Global Alliance for Vaccines and Immunization (GAVI) and Others.
TABLE OF CONTENTS
PART 1. INTRODUCTION
1.1 SCOPE OF THE STUDY
1.2 Publisher RESEARCH REPORT GUIDANCE
PART 2. ASIA PACIFIC VACCINES MARKET - KEY TAKEAWAYS
PART 3. ASIA PACIFIC VACCINES MARKET - MARKET LANDSCAPE
3.1 OVERVIEW
3.2 MARKET SEGMENTATION
 3.2.1 Asia Pacific Vaccines Market - By Technology
 3.2.2 Asia Pacific Market - By Disease Indication
 3.2.3 Asia Pacific Vaccines Market - By Route of Administration
 3.2.4 Asia Pacific Vaccines Market - By Patient Type
 3.2.5 Asia Pacific Vaccines Market - By Country
3.3 PEST ANALYSIS
 3.3.1 Asia Pacific- PEST Analysis
PART 4. ASIA PACIFIC VACCINES MARKET- KEY MARKET DYNAMICS
4.1 KEY MARKET DRIVERS
 4.1.1 Rising Number of Awareness Programs, Campaigns and Conferences for Vaccination in Asia Pacific
 4.1.2 Growing Vaccine Production in Asia Pacific.
4.2 KEY MARKET RESTRAINTS
 4.2.1 Mistrust of Immunization in the Asia Pacific Region.
4.3 KEY MARKET OPPORTUNITIES
 4.3.1 Increasing Incidences of Infectious and Contagious Diseases
4.4 FUTURE TRENDS
 4.4.1 Vaccine Research in Asia
4.5 IMPACT ANALYSIS
PART 5. VACCINES MARKET - ASIA PACIFIC ANALYSIS
5.1 ASIA PACIFIC VACCINES MARKET REVENUE FORECASTS AND ANALYSIS
5.2 MARKET POSITIONING
5.3 PERFORMANCE OF KEY PLAYERS
 5.3.1 GlaxoSmithKline plc
PART 6. ASIA PACIFIC VACCINES MARKET ANALYSIS - BY TECHNOLOGY
6.1 OVERVIEW
6.2 ASIA PACIFIC VACCINES MARKET, BY TYPE, 2018 & 2027 (%)
6.3 ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY TECHNOLOGY (US$ MN)
6.4 ASIA PACIFIC RECOMBINANT VACCINES MARKET
 6.4.1 Overview
 6.4.2 Asia Pacific Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.5 ASIA PACIFIC CONJUGATE VACCINES MARKET
 6.5.1 Overview
 6.5.2 Asia Pacific Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.6 ASIA PACIFIC LIVE ATTENUATED VACCINES MARKET
 6.6.1 Overview
 6.6.2 Asia Pacific Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.7 ASIA PACIFIC INACTIVATED VACCINES MARKET
 6.7.1 Overview
 6.7.2 Asia Pacific Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
6.8 ASIA PACIFIC TOXOID VACCINES MARKET
 6.8.1 Overview
 6.8.2 Asia Pacific Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
PART 7. ASIA PACIFIC VACCINES MARKET ANALYSIS - BY DISEASE INDICATION
7.1 OVERVIEW
7.2 ASIA PACIFIC VACCINES MARKET, BY DISEASE INDICATION, 2018 & 2027 (%)
7.3 ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY DISEASE INDICATION (US$ MN)
7.4 ASIA PACIFIC DTP (DIPHTHERIA, TETANUS, AND PERTUSSIS) MARKET
 7.4.1 Overview
 7.4.2 Asia Pacific DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
7.5 ASIA PACIFIC INFLUENZA MARKET
 7.5.1 Overview
 7.5.2 Asia Pacific Influenza Market Revenue and Forecast to 2027 (US$ Mn)
7.6 ASIA PACIFIC HEPATITIS MARKET
 7.6.1 Overview
 7.6.2 Asia Pacific Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
7.7 ASIA PACIFIC OTHER DISEASES MARKET
 7.7.1 Overview
 7.7.2 Asia Pacific Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
PART 8. ASIA PACIFIC VACCINES MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ASIA PACIFIC VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)
8.3 ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY ROUTE OF ADMINISTRATION (US$ MN)
8.4 ASIA PACIFIC ORAL MARKET
 8.4.1 Overview
 8.4.2 Asia Pacific Oral Market Revenue and Forecast to 2027 (US$ Mn)
8.5 ASIA PACIFIC INJECTABLE MARKET
 8.5.1 Overview
 8.5.2 Asia Pacific Injectable Market Revenue and Forecast to 2027 (US$ Mn)
8.6 ASIA PACIFIC OTHER ROUTES OF ADMINISTRATION MARKET
 8.6.1 Overview
 8.6.2 Asia Pacific Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
PART 9. ASIA PACIFIC VACCINES MARKET ANALYSIS - BY PATIENT TYPE
9.1 OVERVIEW
9.2 ASIA PACIFIC VACCINES MARKET, BY PATIENT TYPE, 2018 & 2027 (%)
9.3 ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027, BY PATIENT TYPE (US$ MN)
9.4 ASIA PACIFIC PEDIATRIC MARKET
 9.4.1 Overview
 9.4.2 Asia Pacific Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
9.5 ASIA PACIFIC ADULTS MARKET
 9.5.1 Overview
 9.5.2 Asia Pacific Adults Market Revenue and Forecast to 2027 (US$ Mn)
PART 10. ASIA PACIFIC VACCINES MARKET REVENUE AND FORECASTS TO 2027
 10.1.1 Overview
 10.1.2 Asia Pacific Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.3 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.4 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.5 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.6 Asia Pacific Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
 10.1.7 Asia Pacific Vaccines Market Revenue and Forecasts to 2027, By Country (%)
 10.1.8 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.9 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.9.1 China Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.9.2 China Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.9.3 China Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.9.4 China Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
 10.1.10 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.11 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.11.1 Japan Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.11.2 Japan Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.11.3 Japan Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.11.4 Japan Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
 10.1.12 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.13 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.13.1 India Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.13.2 India Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.13.3 India Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.13.4 India Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
 10.1.14 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.15 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.15.1 Australia Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.15.2 Australia Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.15.3 Australia Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.15.4 Australia Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
 10.1.16 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.17 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
 10.1.17.1 South Korea Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
 10.1.17.2 South Korea Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
 10.1.17.3 South Korea Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
 10.1.17.4 South Korea Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
PART 11. VACCINES MARKET- KEY COMPANY PROFILES
11.1 PFIZER INC.
 11.1.1 Key Facts
 11.1.2 Business Description
 11.1.3 Financial Overview
 11.1.4 Product Portfolio
 11.1.5 SWOT Analysis
 11.1.6 Key Developments
11.2 GLAXOSMITHKLINE PLC.
 11.2.1 Key Facts
 11.2.2 Business Description
 11.2.3 Financial Overview
 11.2.4 Product Portfolio
 11.2.5 SWOT Analysis
 11.2.6 Key Developments
11.3 MERCK & CO., INC.
 11.3.1 Key Facts
 11.3.2 Business Description
 11.3.3 Financial Overview
 11.3.4 Product Portfolio
 11.3.5 SWOT Analysis
 11.3.6 Key Developments
11.4 SANOFI
 11.4.1 Key Facts
 11.4.2 Business Description
 11.4.3 Financial Information
 11.4.4 Product Portfolio
 11.4.5 SWOT Analysis
 11.4.6 Key Developments
11.5 JOHNSON & JOHNSON SERVICES, INC.
 11.5.1 Key Facts
 11.5.2 Business Description
 11.5.3 Financial Overview
 11.5.4 Product Portfolio
 11.5.5 SWOT Analysis
 11.5.6 Key Developments
11.6 PANACEA BIOTEC LIMITED
 11.6.1 Key Facts
 11.6.2 Business Description
 11.6.3 Financial Information
 11.6.4 Product Portfolio
 11.6.5 SWOT Analysis
 11.6.6 Key Developments
11.7 ASTELLAS PHARMA INC.
 11.7.1 Key Facts
 11.7.2 Business Description
 11.7.3 Financial Overview
 11.7.4 Product Portfolio
 11.7.5 Swot Analysis
 11.7.6 Key Developments
11.8 NOVAVAX, INC.
 11.8.1 Key Facts
 11.8.2 Business Description
 11.8.3 Financial Information
 11.8.4 Product Pipeline
 11.8.5 SWOT Analysis
 11.8.6 Key Developments
11.9 VBI VACCINES INC.
 11.9.1 Key Facts
 11.9.2 Business Description
 11.9.3 Financial Information
 11.9.4 Product Portfolio
 11.9.5 SWOT Analysis
 11.9.6 Key Developments
11.10 BAVARIAN NORDIC
 11.10.1 Key Facts
 11.10.2 Business Description
 11.10.3 Financial Information
 11.10.4 Product Pipeline
 11.10.5 SWOT Analysis
 11.10.6 Key Developments
PART 12. APPENDIX
12.1 ABOUT Publisher
12.2 GLOSSARY OF TERMS
12.3 METHODOLOGY
 12.3.1 Coverage
 12.3.2 Secondary Research
 12.3.3 Primary Research
LIST OF TABLES
LIST OF FIGURES
The List of Companies
1. PFIZER INC
2. GlaxoSmithKline plc.
3. Merck & Co., Inc.
4. Sanofi
5. Johnson & Johnson Services, Inc
6. Panacea Biotec Limited
7. Astellas Pharma Inc.
8. NOVAVAX, INC.
9. VBI Vaccines Inc
10. Bavarian Nordic